TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
NYSE · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jun 17, 2026
$17.86
· of 52w range
· above low
· to high
$12.9952w low
$19.1052w high
P/E
-0.2
EPS
$-96.75
Revenue
$4.51T
your badges
52W Range
$13–$19
Analyst Rating
BUY
Price Target
$22
P/E
-0.2
ROE
-2.1%
Net Profit Margin
-3.4%
Your badge strip is empty — pin a metric anywhere on this page.
TAK Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$17.86
P/E
-0.2
EPS
$-96.75
Revenue
$4.51T
ROE
-2.1%
52W Range
$13–$19
TAK Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$4.51T2017-03-31 → 2026-03-31
EPS$-96.752017-03-31 → 2026-03-31
Free Cash Flow$865.43B2019-03-31 → 2026-03-31
Net margin-3.4%2019-03-31 → 2026-03-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | TAK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | -0.25Y avg ≈0.1 | ≈0.1 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | TAK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin | 0.14%5Y avg ≈7.5% | ≈7.5% | · | · | |
| EBITDA Margin | 16.1%5Y avg ≈24.1% | ≈24.1% | · | · | |
| Pretax Margin | -3.2%5Y avg ≈3.9% | ≈3.9% | · | · | |
| Net Profit Margin | -3.4%5Y avg ≈3.3% | ≈3.3% | · | · | |
| ROA | -1.0%5Y avg ≈0.96% | ≈0.96% | · | · | |
| ROE | -2.1%5Y avg ≈2.2% | ≈2.2% | · | · | |
| ROIC | 0.09%5Y avg ≈4.8% | ≈4.8% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | TAK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 1.15Y avg ≈1.1 | ≈1.1 | · | · | |
| Quick Ratio | 0.35Y avg ≈0.4 | ≈0.4 | · | · | |
| Interest Coverage | 0.05Y avg ≈2.5 | ≈2.5 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
No data for this ratio group yet
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | TAK | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.35Y avg ≈0.3 | ≈0.3 | · | · | |
| Inventory Turnover | 1.25Y avg ≈1.3 | ≈1.3 | · | · | |
| Receivables Turnover | 5.85Y avg ≈5.9 | ≈5.9 | · | · | |
| Revenue / Employee | ≈$95.8M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Payout Ratio-204.7%
Annualized Payout≈$0.68
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Mar 31, 2025 | $0.34 | USD | ≈4.5% |
| Sep 30, 2024 | $0.33 | USD | ≈4.3% |
| Mar 27, 2024 | $0.29 | USD | ≈2.1% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
9.1%
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $70.54 | $54.92 | 28.4% | |
| March 31, 2026 | $-15.56 | $-24.26 | 35.8% | |
| Dec. 31, 2025 | $65.65 | $34.44 | 90.6% | |
| Sept. 30, 2025 | $-7.48 | $34.14 | -121.9% | |
| June 30, 2025 | $79.40 | $57.15 | 38.9% | |
| March 31, 2025 | $-65.35 | $-55.79 | -17.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.51T | $4.58T | $4.26T | $4.03T | $3.57T | $3.20T | $3.29T | $2.10T | $1.77T | |
| Cost of Revenue | $1.57T | $1.58T | $1.43T | $1.24T | $1.11T | $994.31B | $1.09T | $651.73B | $495.92B | |
| R&D Expense | $675.92B | $730.23B | $729.92B | $633.33B | $526.09B | $455.83B | $492.38B | $368.30B | $325.44B | |
| Operating Income | $6.22B | $342.59B | $214.07B | $490.50B | $460.84B | $509.27B | $100.41B | $237.69B | $241.79B | |
| Interest Expense | $148.12B | $137.31B | $119.53B | $116.97B | $122.43B | $130.81B | $149.01B | $48.16B | $10.04B | |
| Interest Income | $211.18B | $46.55B | $52.09B | $62.91B | $23.70B | $105.52B | $27.83B | $16.84B | $39.54B | |
| Pretax Income | $-142.35B | $175.08B | $52.79B | $375.09B | $302.57B | $366.24B | $-60.75B | $127.61B | $217.21B | |
| Income Tax | $9.77B | $66.94B | $-91.41B | $58.05B | $72.41B | $-9.94B | $-105.04B | $-7.47B | $30.50B | |
| Net Income | $-152.39B | $107.93B | $144.07B | $317.02B | $230.06B | $376.00B | $44.24B | $135.19B | $186.89B | |
| EPS (Basic) | $-96.75 | $68.36 | $92.09 | $204.29 | $147.14 | $240.72 | $28.41 | $140.61 | $239.35 | |
| EPS (Diluted) | $-96.75 | $67.23 | $91.16 | $201.94 | $145.87 | $238.96 | $28.25 | $139.82 | $237.56 | |
| Shares (Basic) | 1,575,062,000 | 1,578,873,000 | 1,564,450,000 | 1,551,809,000 | 1,563,501,000 | 1,562,006,000 | 1,557,204,000 | 961,477,000 | 780,812,000 | |
| Shares (Diluted) | 1,575,062,000 | 1,605,323,000 | 1,580,343,000 | 1,569,872,000 | 1,577,169,000 | 1,573,537,000 | 1,566,204,000 | 966,897,000 | 786,707,000 | |
| EBITDA | $727.34B | $1.10T | $942.08B | $1.15T | $1.04T | $1.07T | $684.06B | $477.42B | · |
Balance Sheet
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $144.76B | $233.74B | $205.19B | $229.56B | $389.06B | $335.03B | $188.64B | $462.89B | $243.32B | |
| Receivables | $844.31B | $709.47B | $668.40B | $649.43B | $696.64B | $783.09B | $757.00B | $741.91B | $420.25B | |
| Inventory | $1.40T | $1.22T | $1.21T | $986.46B | $853.17B | $753.88B | $759.60B | $919.67B | $212.94B | |
| Current Assets | $3.09T | $2.52T | $2.56T | $2.40T | $2.59T | $2.71T | $2.47T | $2.99T | $1.08T | |
| PP&E (Net) | · | · | · | $1.69T | $1.58T | $1.45T | $1.39T | $1.33T | $536.80B | |
| Goodwill | $5.81T | $5.32T | $5.41T | $4.79T | $4.41T | $4.03T | $4.01T | $4.24T | $1.03T | |
| Intangibles | $3.42T | $3.63T | $4.27T | $4.27T | $3.82T | $3.91T | $4.17T | $4.75T | $1.01T | |
| Total Assets | $15.51T | $14.25T | $15.11T | $13.96T | $13.18T | $12.91T | $12.82T | $13.79T | $4.11T | |
| Accounts Payable | $491.35B | $475.54B | $547.52B | $649.23B | $516.30B | $343.84B | $318.82B | $327.39B | $240.26B | |
| Current Liabilities | $2.83T | $2.51T | $2.31T | $2.48T | $2.15T | $1.77T | $2.18T | $2.55T | $737.51B | |
| Total Liabilities | $8.08T | $7.31T | $7.83T | $7.60T | $7.49T | $7.74T | $8.09T | $8.61T | $2.09T | |
| Retained Earnings | $712.38B | $1.19T | $1.39T | $1.54T | $1.48T | $1.51T | $1.37T | $1.60T | $1.56T | |
| Stockholders' Equity | $7.43T | $6.94T | $7.27T | $6.35T | $5.68T | $5.17T | $4.72T | $5.18T | $2.00T |
Cash Flow
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $721.13B | $761.40B | $728.00B | $664.40B | $583.15B | $559.67B | $583.65B | $247.69B | $182.13B | |
| Other Non-cash | $472.69B | $187.86B | $-155.72B | $-4.26B | $309.89B | $75.25B | $41.86B | $-53.09B | · | |
| Operating Cash Flow | $1.04T | $1.06T | $716.34B | $977.16B | $1.12T | $1.01T | $669.75B | $328.48B | $377.85B | |
| CapEx | $176.00B | $200.79B | $175.42B | $140.66B | $123.25B | $111.21B | $127.08B | $77.68B | $67.00B | |
| Investing Cash Flow | $-369.14B | $-367.06B | $-463.86B | $-607.10B | $-198.12B | $393.53B | $292.12B | $-2.84T | $-93.34B | |
| Dividends Paid | $311.90B | $302.50B | $287.19B | $279.42B | $283.67B | $283.36B | $282.58B | $142.95B | $141.89B | |
| Financing Cash Flow | $-496.82B | $-751.42B | $-354.42B | $-709.15B | $-1.07T | $-1.09T | $-1.01T | $2.95T | $-326.23B | |
| Free Cash Flow | $865.43B | $856.39B | $540.92B | $836.50B | $999.85B | $899.73B | $542.67B | $250.80B | · | |
| Levered FCF | $707.14B | $771.58B | $214.42B | $737.63B | $906.72B | $765.37B | $651.30B | $195.48B | · |
Profitability
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.14% | 7.5% | 5.0% | 12.2% | 12.9% | 15.9% | 3.0% | 9.8% | · | |
| Net Margin | -3.4% | 2.4% | 3.4% | 7.9% | 6.5% | 11.8% | 1.3% | 5.2% | · | |
| Pretax Margin | -3.2% | 3.8% | 1.2% | 9.3% | 8.5% | 11.5% | -1.8% | 4.5% | · | |
| EBITDA Margin | 16.1% | 24.1% | 22.1% | 28.7% | 29.2% | 33.4% | 20.8% | 22.8% | · | |
| ROA | -1.0% | 0.74% | 0.99% | 2.3% | 1.8% | 2.9% | 0.33% | 1.2% | · | |
| ROE | -2.1% | 1.5% | 2.1% | 5.3% | 4.2% | 7.6% | 0.89% | 3.0% | · | |
| ROIC | 0.09% | 3.0% | 8.0% | 6.5% | 6.2% | 10.1% | -1.6% | 4.6% | · |
Liquidity & Solvency
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.0 | 1.1 | 1.0 | 1.2 | 1.5 | 1.1 | 1.2 | · | |
| Quick Ratio | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.6 | 0.4 | 0.5 | · | |
| Interest Coverage | 0.0 | 2.5 | 1.8 | 4.2 | 3.8 | 3.9 | 0.7 | 4.3 | · |
Efficiency
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | · | |
| Inventory Turnover | 1.2 | 1.3 | 1.3 | 1.4 | 1.4 | 1.3 | 1.3 | 1.1 | · | |
| Receivables Turnover | 5.8 | 6.7 | 6.5 | 6.0 | 4.8 | 4.2 | 4.4 | 3.6 | · |
Per Share
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $2860.66 | $2853.97 | $2698.00 | $2565.48 | $2262.92 | $2032.24 | $2101.38 | $2169.03 | · | |
| Cash Flow / Share | $661.20 | $658.55 | $453.28 | $622.44 | $712.10 | $642.46 | $427.63 | $339.72 | · | |
| EPS (TTM) | $-96.75 | $67.23 | $91.16 | $201.94 | $145.87 | $238.96 | $28.25 | $139.82 | · |
Valuation (TTM)
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.51T | $4.58T | $4.26T | $4.03T | $3.57T | $3.20T | $3.29T | $2.10T | · | |
| Net Income TTM | $-152.39B | $107.93B | $144.07B | $317.02B | $230.06B | $376.00B | $44.24B | $135.19B | · | |
| P/E | -0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.5 | 0.1 | · | |
| Earnings Yield | -522.4% | 452.1% | 656.3% | 1225.4% | 1018.7% | 1308.6% | 186.1% | 686.4% | · | |
| Payout Ratio | -204.7% | 280.3% | 199.3% | 88.1% | 123.3% | 75.4% | 638.7% | 131.0% | · | |
| Annual Payout | $311.90B | $302.50B | $287.19B | $279.42B | $283.67B | $283.36B | $282.58B | $142.95B | · |
No quarterly filings for TAK
We don't have SEC filings for this ticker yet.
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Revenue | $4.51T | $4.58T | $4.26T | $4.03T | $3.57T |
| Operating Margin % | 0.14% | 7.5% | 5.0% | 12.2% | 12.9% |
| Net Income | $-152.39B | $107.93B | $144.07B | $317.02B | $230.06B |
| Diluted EPS | $-96.75 | $67.23 | $91.16 | $201.94 | $145.87 |
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.0 | 1.1 | 1.0 | 1.2 |
| Quick Ratio | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 |
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $865.43B | $856.39B | $540.92B | $836.50B | $999.85B |
Institutional owners (13F) 409 filers · $1.7B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
409
Value held
$1.7B
New positions
64
Exited positions
38
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 64 (0 vs prior Q) | 38 (+5 vs prior Q) | 144 (-28 vs prior Q) | 99 (+41 vs prior Q) | +6.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Capital Research Global Investors | $309,341,810 | 19,297,680 | 18.23% | Shares |
| FMR LLC | $153,876,803 | 9,599,302 | 9.07% | Shares |
| MORGAN STANLEY | $112,128,655 | 6,994,924 | 6.61% | Shares |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $96,993,859 | 6,050,771 | 5.72% | Shares |
| GOLDMAN SACHS GROUP INC | $82,154,258 | 5,125,032 | 4.84% | Shares |
| BRANDES INVESTMENT PARTNERS, LP | $72,765,928 | 4,539,347 | 4.29% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $59,838,772 | 3,732,924 | 3.53% | Shares |
| BlackRock, Inc. | $59,121,313 | 3,688,166 | 3.48% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $41,165,040 | 2,568,000 | 2.43% | Shares |
| Qube Research & Technologies Ltd | $35,385,135 | 2,207,432 | 2.09% | Shares |
| FIRST TRUST ADVISORS LP | $33,902,011 | 2,114,912 | 2.00% | Shares |
| D. E. Shaw & Co., Inc. | $32,852,956 | 2,049,467 | 1.94% | Shares |
| MANAGED ASSET PORTFOLIOS, LLC | $29,236,866 | 1,823,884 | 1.72% | Shares |
| NORTHERN TRUST CORP | $27,897,218 | 1,740,313 | 1.64% | Shares |
| VAN ECK ASSOCIATES CORP | $26,834,300 | 1,674,005 | 1.58% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $25,617,763 | 1,598,174 | 1.51% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $24,456,751 | 1,525,686 | 1.44% | Shares |
| Quantinno Capital Management LP | $22,484,494 | 1,402,650 | 1.32% | Shares |
| WELLS FARGO & COMPANY/MN | $18,447,659 | 1,150,820 | 1.09% | Shares |
| MILLENNIUM MANAGEMENT LLC | $16,842,689 | 1,050,698 | 0.99% | Shares |
| UBS Group AG | $14,608,444 | 911,319 | 0.86% | Shares |
| Crossmark Global Holdings, Inc. | $12,564,875 | 783,835 | 0.74% | Shares |
| JANE STREET GROUP, LLC | $12,327,070 | 769,000 | 0.73% | Call option |
| CITADEL ADVISORS LLC | $12,165,167 | 758,900 | 0.72% | Call option |
| JPMORGAN CHASE & CO | $11,903,771 | 744,916 | 0.70% | Shares |
| STIFEL FINANCIAL CORP | $11,587,485 | 722,863 | 0.68% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $11,447,712 | 714,143 | 0.67% | Shares |
| ROYAL BANK OF CANADA | $11,107,000 | 692,900 | 0.65% | Shares |
| Focus Partners Wealth | $10,901,024 | 679,950 | 0.64% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $9,922,907 | 619,021 | 0.58% | Shares |
| Creative Planning | $9,373,982 | 584,777 | 0.55% | Shares |
| AMERICAN CENTURY COMPANIES INC | $9,370,497 | 584,560 | 0.55% | Shares |
| LPL Financial LLC | $8,900,303 | 555,228 | 0.52% | Shares |
| Balyasny Asset Management L.P. | $8,196,716 | 511,336 | 0.48% | Shares |
| TWO SIGMA INVESTMENTS, LP | $7,786,300 | 485,733 | 0.46% | Shares |
| US BANCORP \DE\ | $7,481,425 | 466,714 | 0.44% | Shares |
| PFM Health Sciences, LP | $7,120,093 | 444,173 | 0.42% | Shares |
| Bleakley Financial Group, LLC | $6,940,285 | 432,956 | 0.41% | Shares |
| RAYMOND JAMES FINANCIAL INC | $6,552,092 | 408,739 | 0.39% | Shares |
| CITIGROUP INC | $6,355,206 | 396,457 | 0.37% | Shares |
| FEDERATED HERMES, INC. | $6,041,034 | 376,858 | 0.36% | Shares |
| QRG CAPITAL MANAGEMENT, INC. | $5,975,215 | 372,752 | 0.35% | Shares |
| Ethic Inc. | $5,854,998 | 365,253 | 0.35% | Shares |
| Vestmark Advisory Solutions, Inc. | $5,638,878 | 351,770 | 0.33% | Shares |
| ASSETMARK, INC | $5,044,432 | 314,687 | 0.30% | Shares |
| Mariner, LLC | $4,939,586 | 308,157 | 0.29% | Shares |
| BANK OF AMERICA CORP /DE/ | $4,926,218 | 307,312 | 0.29% | Shares |
| TWO SIGMA ADVISERS, LP | $4,652,056 | 298,400 | 0.27% | Shares |
| Hudson Bay Capital Management LP | $4,408,250 | 275,000 | 0.26% | Shares |
| Pathstone Holdings, LLC | $3,843,704 | 239,306 | 0.23% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Takeda Pharmaceutical Company Limited, Takeda Vaccines Inc. ×9 filings | Sept. 19, 2025 | 0.00% | Amendment | M&A / sale | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 25 insiders · 16 officers · 11 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Julie So-Young Kim | President and CEO | Aug. 10, 2026 S | 391,489 | 0 | 1 | $-1,523,439 |
| Milano Furuta | Chief Financial Officer | July 1, 2026 A | 70,200 | 0 | 0 | $0 |
| Andrew Stewart Plump | President, R&D | Sept. 2, 2026 S | 145,465 | 0 | 3 | $-5,339,939 |
| Ramy Riad Ahmed Ibrahim | President, PDT BU | Aug. 10, 2026 S | 102,588 | 0 | 1 | $-124,437 |
| Rhonda Janice Pacheco | President, U.S. Business Unit | Aug. 10, 2026 S | 182,507 | 0 | 1 | $-289,007 |
| Giles Richard Platford | President, IBU | Aug. 10, 2026 S | 315,838 | 0 | 1 | $-531,519 |
| Teresa Marie Bitetti | President, OBU | Aug. 10, 2026 S | 252,010 | 0 | 1 | $-855,205 |
| Asuka Miyabashira | President, Japan Pharma B.U. | July 1, 2026 A | 4,500 | 0 | 0 | $0 |
| Lauren Rusckowski Duprey | Chief Transformation Officer | Sept. 14, 2026 S | 191,522 | 0 | 2 | $-1,454,000 |
| Nicola Deidre Petal Greenway | Chief Human Resources Officer | Aug. 18, 2026 S | 40,049 | 0 | 4 | $-956,791 |
| Awny Samaan Botros Farajallah | Chief Medical Officer | Aug. 10, 2026 S | 116,177 | 0 | 1 | $-239,503 |
| Natalie Anne Marie Furney | Global General Counsel | Aug. 10, 2026 S | 204,298 | 0 | 1 | $-527,843 |
| Elaine Mary Shannon | Pres., Global Supply & Quality | Aug. 10, 2026 S | 63,333 | 0 | 2 | $-425,395 |
| Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | Aug. 10, 2026 S | 176,977 | 0 | 1 | $-392,565 |
| Gabriele Ricci | Chief Data & Tech. Officer | Aug. 10, 2026 S | 171,654 | 0 | 1 | $-429,005 |
| Jennifer Marie Smoter | Chief Comm. & Gov. Officer | July 1, 2026 A | 18,808 | 0 | 0 | $0 |
| Koichiro Kimura | Director | July 1, 2026 A | 1,800 | 0 | 0 | $0 |
| Masami Iijima | Director | July 1, 2026 A | 14,601 | 0 | 0 | $0 |
| Miki Tsusaka | Director | July 1, 2026 A | 8,200 | 0 | 0 | $0 |
| Kimberly A. Reed | Director | July 1, 2026 A | 10,400 | 0 | 0 | $0 |
| Paulus Stoffels | Director | July 1, 2026 A | 3,800 | 0 | 0 | $0 |
| Steven Gillis | Director | July 1, 2026 A | 10,400 | 0 | 0 | $0 |
| Bruce D Broussard | Director | July 1, 2026 A | 4,595 | 0 | 0 | $0 |
| John Maraganore | Director | July 1, 2026 A | 10,400 | 0 | 0 | $0 |
| Christophe Pierre Weber | · | April 27, 2026 A | 418,803 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 3 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
TAK Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 21 analysts
BUY
Median target
$22.15
+24.0%
5 23.8%
Strong Buy
9 42.9%
Buy
7 33.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
3 analysts · 2026-09-30Mean target $22.05 +23.5%
← Below all targets
Current price $17.86
Low$21.00
Mean$22.05
High$23.00
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 20-F filed Jun 17, 2026